TORRENT PHARMACEUTICALS LTD. - 500420 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificates27-01-2023
27-01-2023
Pharma stock declares 280% dividend. Check payment date, other details
Torrent Pharma said that the dividend is expected to be paid/ dispatched on or around 14th February, 202326-01-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Audio Recording Of Conference Call With Analysts / Investors On Financial Results For The Quarter And Nine Months Ended 31St December, 2022
In continuation of our letter dated 12-Jan-23 and pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the audio recording of Conference call with Analysts / Investors on Financial Results of the Company for the quarter and nine months ended 31st December, 2022, has been placed on the Company's website at https://www.torrentpharma.com/pdf/investors/Audio_Recording31122022.mp325-01-2023
Torrent Pharmaceuticals Results Earnings Call for Q3FY23
Conference Call with Torrent Pharmaceuticals Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.25-01-2023
Torrent Pharma Q3 net profit up 14% to Rs 283 cr; interim dividend declared
Torrent Pharma on Wednesday said its consolidated net profit increased by 14 per cent to Rs 283 crore in the third quarter ended December 31, 2022. The drug firm had reported a net profit of Rs 249 crore in the October-December period of previous fiscal. Net sales increased to Rs 2,459 crore in the quarter under review as against Rs 2,092 crore in the year-ago period, the company said in a regulatory filing. The company's board, which met on Wednesday, declared an interim dividend of Rs 14 (280 per cent) per share of Rs 5 each. On Wednesday, shares of the company ended 1.86 per cent down at Rs 1,557.50 apiece on the BSE.25-01-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Investor Presentation
Presentation to analysts on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 202225-01-2023
Q3FY23 Quarterly Result Announced for Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals announced Q3FY23 results: Revenue at Rs 2,491 crore, up by 18% Gross margins: 71%; Op EBITDA margins: 29.1% Op EBITDA at Rs 724 crore, up by 35% Net profit after tax at Rs 283 crore, up by 14% India: India revenues at Rs 1,259 crore grew by 17% and included revenue from the integration of Curatio Healthcare As per AIOCD secondary data, Torrent’s growth for the quarter was 12% vs IPM growth of 12% Field force has been further expanded and MR strength now stands at 5,300, including Curatio divisions For YTD Dec FY23, revenues were Rs 3,728 crore, up by 15% Brazil: Brazil revenue at Rs 248 crore, up by 36% Constant currency revenue at Rs 159 million, up by 17% As per secondary data set, Torrent’s growth is 19% vs BGx market growth of 13% for the quarter ended in November 22 Growth was aided by performance of top brands and market share gain and strong momentum in the generic segment For YTD Dec FY23, revenues were Rs 617 crore, up by 26% (Constant currency revenue: Rs 397 million, up by 12%) Germany: Germany revenue at Rs 241 crore up by 1% Constant currency revenue was Euro 29 million, up by 4% Sequential recovery in Germany complemented by new tenders and growth of OTC segment For YTD Q3FY23, revenues were Rs 675 crore, down by 10% (Constant currency revenue: Euro 82 million). United States: US revenue at Rs 291 crore, up by 24% Constant currency revenue at US$ 35 million, up by 13% As on December 31, 2022, 48 ANDAs were pending approval with USFDA and 3 tentative approvals were received. During the quarter, 1 ANDAs was filed & 1 ANDAs was approved For YTD Dec FY23, revenues were Rs 882 crore, up by 12% (Constant currency revenue: US$ 111 million, up by 5%) Result PDF25-01-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Dividend Updates
Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")25-01-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Outcome for Submission / Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")25-01-2023
TORRENT PHARMACEUTICALS LTD. - 500420 - Submission / Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')
Submission / Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')25-01-2023